Labcorp (LH)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$283.76-0.22%
Close 2026-07-07 · 1-day change
Reading LH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track LH free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading LH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track LH free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on consistent earnings growth. The current thesis state is intact, supported by recent strong financial performance and management's commitment to guidance increases.
The market seems to have a neutral view on LH, with a valuation that is considered cheap compared to peers. There is a slight expectations gap, indicating that the market may not fully reflect the company's potential for earnings growth.
Fundamentals are likely to remain strong, as management is on track with guidance for adjusted earnings per share, revenue, and free cash flow. However, there is a moderate risk due to the company's history of misses, which could impact future performance.
The thesis hinges on the performance of sector bellwethers like TMO, DHR, and IDXX. If these companies continue to exceed earnings expectations, LH could benefit from positive sector momentum. Conversely, any negative guidance from these peers could pose a risk to LH's outlook.
Over the next 1 to 3 years, LH's performance will depend on its ability to maintain operational strength and navigate sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat and the increase in 2026 Adjusted EPS guidance support this improvement, indicating that the company's growth potential is enhancing. There are no significant threats noted that would counter this positive shift.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: An update to revenue guidance shows strong performance. It also suggests good growth ahead.
Confirms:Labcorp raises its 2026 revenue guidance above $14.80 billion.
Disproves:Labcorp maintains or lowers its 2026 revenue guidance below $14.65 billion.
Why it matters: An increase in EPS guidance means better earnings. This shows success in operations.
Confirms:Labcorp raises its 2026 Adjusted EPS guidance above $18.03.
Disproves:Labcorp keeps its 2026 Adjusted EPS guidance at or below $18.03.
Why it matters: A slowdown in revenue growth could mean problems for Labcorp's business.
Confirms:Q2 revenue growth reported below 5.0% year over year.
Disproves:Q2 revenue growth reported above 6.1% year over year.
Why it matters: Clear guidance on free cash flow shows how Labcorp manages its money and operations.
Confirms one read:Management gives free cash flow guidance above $1.36 billion for 2026.
Confirms the other:Management gives free cash flow guidance below $1.24 billion for 2026.
Why it matters: Free cash flow guidance reflects Labcorp's financial health and ability to invest.
Confirms:Labcorp raises its free cash flow guidance above $1.36 billion.
Disproves:Labcorp keeps its free cash flow guidance at or below $1.24 billion.
Why it matters: Higher EPS guidance shows stronger earnings and more investor confidence in growth.
Confirms:Management raises 2026 Adjusted EPS guidance above what it is now.
Disproves:Management keeps or lowers the 2026 Adjusted EPS outlook.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.